The combo therapy demonstrated an ORR of 87%, with a complete response rate of 65% and a partial response rate of 23%.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

Presenter: Ivor Elrifi, CEO of Tiziana Life Sciences Presentation Title: Treatment of Neuroinflammation with Intranasal Foralumab Presentation Date and Time: June 18, 2025, at 11:45 AM ET Location : ...

A new study uncovers a surprising mechanism by which the SARS-CoV-2 virus, responsible for COVID-19, might cause ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Department of Chemistry, Hunter College of the City University of New York, New York, New York 10028, United States Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...

Current methods of antibody detection, such as conventional serological assays, are limited in terms of the amount of ...